NCT00939237 is a Phase 3 clinical trial of Ateronon in Coronary Heart Disease, sponsored by Brigham and Women's Hospital.

Who is sponsoring NCT00939237?

NCT00939237 is sponsored by Brigham and Women's Hospital.

What drugs are being tested in NCT00939237?

Interventions in NCT00939237: Ateronon, Placebo.

What condition does NCT00939237 study?

NCT00939237 studies Coronary Heart Disease.

Is NCT00939237 still recruiting?

NCT00939237 is currently completed. Last updated 15 August 2014.

Last reviewed 2014-08-15 · How we verify

NCT00939237

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of Ateronon for Carotid Atherosclerosis and Biomarkers in Patients With Stable Coronary Heart Disease

Completed Phase 3 Last updated 15 August 2014

What this trial tests

Phase 3 trial testing Ateronon in Coronary Heart Disease in 213 participants. Completed in 1 May 2011.

Timeline

1 July 2009

Primary endpoint
1 May 2011

1 May 2011

Quick facts

Lead sponsor	Brigham and Women's Hospital
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	213
Start date	1 July 2009
Primary completion	1 May 2011
Estimated completion	1 May 2011
Sites	1 location across United States

Drugs / interventions tested

Ateronon — full drug profile →
Placebo

Conditions studied

Coronary Heart Disease — all drugs for Coronary Heart Disease →

Sponsor

Brigham and Women's Hospital

Who can join

50 and older, any sex, with Coronary Heart Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Carotid intima-media thickness
Time frame: Baseline, 6 months, and 12 months

Sponsor's own description

The purpose of this study is to determine whether Ateronon, a nutritional supplement that contains lycopene from tomatoes has a favorable effect on carotid atherosclerosis, lipid levels, and other biomarkers of coronary heart disease. The trial was stopped early due to insufficient financial support from the initial study collaborator, Cambridge Theranostics Ltd. Collected patient data are sufficient for final trial-based analyses to be conducted with financial support from the new study collaborator, CamNutra Ltd. The data will still be analyzed according to the original study aims.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Coronary Heart Disease

Currently open trials in the same condition.

NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
NCT07110415 — Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by · Phase 4 · recruiting
NCT07451873 — Glycocalyx and Oxidative Stress in Endothelial Function (Part 2) · recruiting
NCT07118930 — Study of Sivelestat Sodium in OPCABG · Phase 2 · recruiting

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

NCT07011758 — Dynamic Treatment Regimes for Opioid Use Disorder · Phase 2 · not yet recruiting
NCT06310018 — Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE · suspended
NCT04519177 — Randomized Trial of a Sleep Disorders Program on Firefighter Safety and Disability ... · NA · not yet recruiting
NCT06355986 — Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · NA · not yet recruiting
NCT06099275 — Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00939237 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brigham and Women's Hospital
Last refreshed: 15 August 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00939237.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing